<p>The Ph' chromosome is a cardinal feature of chronic myelogenous leukemia (CML). Originally described by Nowell and Hungerford (1960) as a small chromosome 22 it was later demonstrated by de Klein and co-workers(1982) to typically result from a reciprocal translocation t(9;22)(q34.1;q11.2). In approximately 5 percent of patients, the Ph' chromosome results from anomalous complex translocation. Detailed studies using in situ hybridization have demonstrated that chromosomes 9 and 22 are usually involved in such translocations. Translocations between chromosome 22 and a chromosome other than 9 rarely occur.<p>The human <u>c-abl</u> sequences represent the cellular homologue of the transforming gene of Abelson Murine Leukemia Virus (A-MuLV). This retrovirus is a recombinant between Moloney Murine Leukemia virus and mouse cellular c-abl sequences (Goff et al., 1980). A-MuLV induces lymphoid tumors following <u>in</u><u>vivo</u> inoculation of the mouse (Potter, 1983; Prekumar et al., 1975). Southern blot analysis of a series of somatic cell hybrids demonstrated that the human <u>c-abl</u> gene is localized on chromosome 9 (Heisterkamp et al., 1982). The finding that a small region of chromosome 9 is translocated to chromosome 22 in CML prompted studies to elucidate whether the <u>abl</u> gene was involved in this disease (de Klein et al., 1982). Bartram and colleagues (1983) first reported that the <u>c-abl</u> gene is translocated in Ph' positive but not in Ph' negative patients while Heisterkamp and co-workers (1983) reported a CML patient with a breakpoint 14 kb 5' of the <u>c-abl</u> sequences homologous to v-abl. This data suggested a role for c- abl in CML, a theory supported by the presence of an abnormally sized abl messenger RNA (Collins et al., 1984; Gale and Canaani, 1984) and abl protein in the CML, cell line K562 (Konopka et al., 1984).<p>The region of chromosome 22 involved in the translocation has also been identified. Cloning of a chimeric breakpoint fragment from a CML, patient (Heisterkamp et al., 1983) enabled the use of a chromosome 22 specific probe. Subsequent Southern blot analysis of the DNA of a number of CML, patients showed that chromosome 22 breakpoints map to a stretch of 5.8 kb of DNA (Groffen, et al., 1984). This area on chromosome 22 was designated breakpoint cluster region or bcr.<p>The investigation described in this thesis was undertaken to gain further insight into the genetic organization of the <u>c-abl</u> gene on the Ph' chromosome and the consequence of the Ph' translocation at the transcription and translation level. Chapter 2 is an extensive review of the genetic basis of CML, and acute lymphoblastic leukemia (All). Discussed is the cytogenetic and molecular aspects of CML, and ALL and the activation of the <u>c-abl</u> protein kinases as a consequence of the Ph' translocation. In Chapter 3, we show that the breakpoint cluster region on chromosome 22 is part of a gene, called <u>phl</u> . Molecular characterization demonstrates that <u>phl</u> . is a large gene oriented with its 5' end towards the centromere and with its 3' end toward the telomere of chromosome 22. As a consequence of the Ph' translocation the 3' end of this gene is translocated to chromosome 9, whereas the S' sequences remain on the Ph' chromosome. Following translocation, the remaining phl sequences become fused to the c-abl gene in a head to tail fashion on chromosome 22. We hypothesized that this genomic<br/>configuration could result in the transcription of a chimeric mRNA consisting of 5' <u>phl</u> and 3' <u>abl</u> sequences. In the study presented in Chapter 4, we analyzed the RNA of CML patients and found strong evidence for this model. Direct proof for the hypothesis was provided by cloning of a chimeric <u>phl</u> /c- <u>abl</u> cDNA in the CML cell line K562, described in Chapter 5. The experiments described herein have also contributed to more information about the genomic organization of the phl. and c-abl genes on the Ph' chromosome.<br/>Reports by Konopka et al. (1985) showing the presence of a larger 210K c- <u>abl</u> protein in the leukemic cells of CML patients initiated the studies described in Chapter 6. We demonstrate that this abnormal c- <u>abl</u> protein is a fusion protein containing amino terminal <u>phl</u> and carboxy terminal <u>abl</u> sequences. This <u>phl</u> /c- <u>abl</u> protein has an elevated tyrosine kinase activity when compared to the normal c- <u>abl</u> protein. In addition, we show in this chapter that the normal phl. gene encodes for a 160 K phosphoprotein exhibiting an associated kinase activity.<br/>A better understanding of the Ph' chromosome at the molecular level has allowed us to develop a probe for the detection of the Ph' translocation. In Chapter 7, we report the results of the clinical trials done at seven medical centers involving more than 400 clinical samples. In this report we demonstrate that the use of DNA probe analysis in the CML diagnostics has several advantages over cytogenetic methods.
|Qualification||Doctor of Philosophy|
|Award date||15 Apr 1988|
|Place of Publication||S.l.|
|Publication status||Published - 1988|
- molecular genetics